#VisualAbstract: Neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen shows high cost-effectiveness for ERBB2-positive breast cancer

byTeddy Guo

December 23, 2020

in StudyGraphics

Reading Time: 1 min read

Special Report: Vaccines in Development Part 3: Oxford/AstraZeneca vaccine showing promise

RelatedReports

StudyGraphics

#VisualAbstract: Continued enzalutamide after progression of metastatic prostate cancer improves progression-free survival

October 26, 2022

Parental debt influences child socioemotional well-being

Chronic Disease

Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists improve diabetes outcomes but are not cost effective

October 20, 2022

StudyGraphics

#VisualAbstract: Chemoradiotherapy with carboplatin is more effective than cetuximab in head and neck squamous cell carcinoma

October 18, 2022

StudyGraphics

#VisualAbstract: Neoadjuvant atezolizumab is not effective for node-positive HER2⁺ breast cancer

October 11, 2022

Severe subtype of acute lymphoblastic leukemia susceptible to FDA-approved kinase inhibitors

Allogeneic anti-CD19 T cell therapy shows a manageable safety profile in pediatric and adult patients with high risk B-cell acute lymphoblastic leukemia

Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Patients with hematological malignancies and concomitant COVID-19 have worse health outcomes

#VisualAbstract: Adjunctive methylprednisolone treatment for hepatitis B acute-on-chronic liver failure associated with increased survival

#VisualAbstract: Enteral water-soluble vitamin A in extremely preterm infants does not reduce severity of bronchopulmonary dysplasia

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

#VisualAbstract: Neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen shows high cost-effectiveness for ERBB2-positive breast cancer

#VisualAbstract: Continued enzalutamide after progression of metastatic prostate cancer improves progression-free survival

Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists improve diabetes outcomes but are not cost effective

#VisualAbstract: Chemoradiotherapy with carboplatin is more effective than cetuximab in head and neck squamous cell carcinoma

Special Report: Vaccines in Development Part 3: Oxford/AstraZeneca vaccine showing promise

Allogeneic anti-CD19 T cell therapy shows a manageable safety profile in pediatric and adult patients with high risk B-cell acute lymphoblastic leukemia

RelatedReports

#VisualAbstract: Continued enzalutamide after progression of metastatic prostate cancer improves progression-free survival

Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists improve diabetes outcomes but are not cost effective

#VisualAbstract: Chemoradiotherapy with carboplatin is more effective than cetuximab in head and neck squamous cell carcinoma

#VisualAbstract: Neoadjuvant atezolizumab is not effective for node-positive HER2⁺ breast cancer

Allogeneic anti-CD19 T cell therapy shows a manageable safety profile in pediatric and adult patients with high risk B-cell acute lymphoblastic leukemia

Patients with hematological malignancies and concomitant COVID-19 have worse health outcomes

#VisualAbstract: Enteral water-soluble vitamin A in extremely preterm infants does not reduce severity of bronchopulmonary dysplasia

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2MM+ Premium Access

Recent Reports

Want more physician-written
medical news?

#VisualAbstract: Neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen shows high cost-effectiveness for ERBB2-positive breast cancer

RELATED REPORTS

Special Report: Vaccines in Development Part 3: Oxford/AstraZeneca vaccine showing promise

Allogeneic anti-CD19 T cell therapy shows a manageable safety profile in pediatric and adult patients with high risk B-cell acute lymphoblastic leukemia

RelatedReports

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2MM+ Premium Access

Recent Reports

Want more physician-written medical news?

Want more physician-written
medical news?